Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in HRRD+ Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
NCT03377556Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of talazoparib in squamous cell carcinoma of the lung (LSCC), sponsored by SWOG Cancer Research Network. Started Mar 2017; status: completed.
02
Drugs
talazoparib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT03377556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377556.